Rainbow Childrens Medicare Ltd Q4 FY26 Earnings Call: Aspires ~20% Growth, 900+ Beds Under Execution

Rainbow Childrens Medicare Ltd held its Q4 FY26 earnings call on May 23, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Strong Quarter with 24% Revenue Growth, PAT up 38% YoY

• Rs.460 Cr revenuein Q4 FY2025-2026 — up 24% YoY; full-year FY2025-2026 revenue at Rs.1,703 Cr (+12% vs FY2024-2025),dragged by seasonal weakness of 10-12% of top line.
• Rs.145 Cr EBITDAin Q4 FY2025-2026 — up 26% YoY; full-year FY2025-2026 EBITDA at Rs.544 Cr (+11% vs FY2024-2025); Q4 margin of 31.5% and full-year margin of 32%.
• Rs.78.2 Cr PATin Q4 FY2025-2026 — up 38% YoY;ex-deferred tax adjustment, PAT growth stood at ~17%; full-year FY2025-2026 PAT at Rs.282 Cr (+15.3% vs FY2024-2025).
• Volume growth remained strong— inpatient discharges +18% YoY, outpatient volumes +19%, deliveries +22% in Q4 FY2025-2026, reflecting broad-based demand across mature and new hospitals.
• Payer mix balancedat 47.5% cash and ~52% insurance during Q4 FY2025-2026.
• Cash position of Rs.594 Cras of Q4 FY2025-2026 — management confirmed the company is "well-positioned to fund all planned expansions through internal resources."

900+ Beds in Execution Phase Across Five Cities

• 900+ beds in active execution— management expects completion in roughly 2.5 years (by ~FY 2027-2028 to FY 2028-2029), spanning Coimbatore, Gurugram, Pune, Bengaluru, and Indore.
• Coimbatore 130-bed hubunder active construction — scheduled to begin operations in H2 FY 2027-2028.
• Gurugram development— a 125-bed spoke (Sector 56) starting H2 FY 2027-2028 and a 325-bed super-specialty hub (Sector 44) starting Q1 FY 2028-2029; total additional Gurgaon CAPEX of Rs.400 Cr over the next two FYs (FY 2027-2028 and FY 2028-2029).
• Pune 150-bed greenfieldwith excavation in progress (timeline unspecified);Bengaluru 80-bed spoke(Seagully) with lease signed (timeline unspecified).
• Indore 100-bed build-to-suitin permission stage — Rainbow will build a semi-warm shell and lease it to a partner on a 20–30 year lease, with partner bearing interior/medical capex; Rainbow's own capex estimated at Rs.65–70 lakh per bed, commissioning in ~2 years (by ~FY 2027-2028).
• Annual maintenance CAPEXpegged at Rs.40–45 Cr; growth CAPEX for 450 new beds ex-Gurgaon estimated at Rs.300–350 Cr for Coimbatore, Pune, and Indore, with per-bed CAPEX of Rs.65–70 lakh.

Mature Hospital Occupancy Recovers to 52%; ARPOB Grows 8% YoY

• Mature hospital occupancy of 52%in Q4 FY2025-2026 — recovered from a seasonal dip; management targets 60% for mature units in FY 2027-2028 and blended occupancy of 56-57% for the coming year (FY 2026-2027).
• Longer-term blended occupancy target of 56-58%at the group level — management stated this range will deliver desired financial metrics (period unspecified).
• ARPOB grew ~8% YoYin Q4 FY2025-2026 — driven by case-mix improvement and fertility segment contribution, with pricing also a factor; management guided ARPP (average revenue per patient) growth of 5-6% as a better pricing metric (period unspecified).
• ALOS stable at 2.7-2.75 days— industry best with limited scope for further reduction;case-mix changes (e.g., higher obstetrics share) could lower it modestly.
• Obstetrics share rose to ~32%in Q4 FY2025-2026 from 28-30% earlier, reflecting improved case mix and reduced seasonal dependency.
• Growth was broad-basedacross key geographies — Hyderabad, Bangalore, Chennai, and Andhra Pradesh in Q4 FY2025-2026.

Hub-and-Spoke, M&A, and a Novel Indore Partnership Model

• Hub-and-spoke model applied market-by-market— management stated it is "not specific about geographies" and open to opportunities across India; smaller cities may need a single hospital, while larger cities like Pune warrant a hub-and-spoke structure.
• M&A strategy targets 50+ bed assetsscalable to 100 beds, with active consideration of larger multi-unit players; a formal growth plan for new geographies will be announced in ~3 months (by August 2026, within FY 2026-2027).
• Indore exclusive arrangement from August 2026(FY 2026-2027) — Rainbow will operate pediatric and obstetrics services within a doctor entrepreneur's 200-bed multi-specialty hospital, deploying its own doctors and nurses with ~25 ICU beds; revenue accrues directly to Rainbow (not an O&M contract).
• Guwahati acquisition integrated— management "actively considering further opportunities" in the North East region.
• Rainbow performed ~20,000 deliveries annuallyand ranks as the second or third largest maternity chain in India, with hospitals averaging above 50 beds;management views consolidation among maternity peers as not materially impactfulgiven Rainbow's scale and clinical focus.
• Super-specialty expansion underway— Hyderabad has a complete super-specialty stack; Bangalore has 60-70% coverage with ongoing build-out; Chennai performed 10 liver transplants in its first year; a significant liver transplant ramp-up is planned for FY 2026-2027.

IVF Growth Guided at 25% YoY; International Revenue Flat on Geopolitical Headwinds

• IVF revenue contributed 3.7%of total revenue in FY 2025-2026 (Rs.61.4 Cr), with Q4 FY2025-2026 showing sequential improvement to 4.1%; management guided for "25% YoY growth in IVF revenue over the next three years" targeting FY 2027-2028 to FY 2029-2030, driven by standalone fertility centers in Bangalore and Hyderabad.
• International patient revenue flat at Rs.28.9 Crfor FY 2025-2026 —impacted by geopolitical issues in Bangladesh, Somalia, Nigeria and Middle East flight disruptions from the war escalation in Q4.
• Pharmacy revenue not disclosedseparately for Q4 FY2025-2026 or full FY 2025-2026; management stated pharmacy cost is approximately 12-13% of pharmacy sales, implying margins exist.
• Organic IP discharge growth of ~9-10%in Q4 FY2025-2026, with acquired units (Guwahati and Warangal) contributing 7-8% to revenue; management expects more visible impact from digital/marketing initiatives (new CRM and hospital information software) by end of Q1 FY 2026-2027.
• Seasonal business weaknessdragged FY 2025-2026 revenue growth to 12% (vs a potential 18-20% without seasonal impact); management aims to reduce seasonal dependency by broadening specialty mix and increasing tertiary care share.
• Management cited a "CRISIL industry report on the pediatric market"currently in progress that will provide more authentic market share data once finalized (third-party study, not a company commitment).

Debt-Free with Rs.594 Cr Cash; ~20% Growth Aspiration for FY27

• Debt-free balance sheetas of Q4 FY 2025-2026 — cash and equivalents of Rs.594 Cr (management separately cited ~Rs.700 Cr in another context); all planned capex for the 900-bed pipeline will be funded entirely through internal accruals, with no debt planned.
• Management aspires to ~20% growthin FY 2026-2027 while maintaining margins, following FY 2025-2026 revenue of Rs.1,703 Cr (+12% vs FY 2024-2025) which was impacted by seasonal weakness.
• Q4 FY2025-2026 capex of Rs.61 Crand FY 2025-2026 total capex of Rs.217 Cr for expansion and capability upgrades; operating cash flow to pre-Ind AS EBITDA ratio at 2.8% post-tax.
• CEO Abrar Ali Dalal(joined ~four months ago) highlighted Rainbow's differentiated full-time consultant model and is building a data-driven, execution-focused organization through dashboards, structured reviews, and unit-level accountability.
• Quality standardization across 25 hospitals— management acknowledged varying patient experiences; the senior doctor team is actively implementing SOPs and protocolization to ensure a "one Rainbow culture" across all hospitals.